Arcutis Biotherapeutics, Inc.
ARQT
$12.59
-$0.85-6.32%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 54.98% | 45.04% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 59.45% | 45.04% | |||
| Cost of Revenue | 25.48% | 58.86% | |||
| Gross Profit | 64.21% | 43.29% | |||
| SG&A Expenses | -2.06% | 1.11% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.76% | 3.57% | |||
| Operating Income | 80.46% | 21.99% | |||
| Income Before Tax | 74.81% | 20.63% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 74.03% | 20.63% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 74.03% | 20.63% | |||
| EBIT | 80.46% | 21.99% | |||
| EBITDA | 80.94% | 24.32% | |||
| EPS Basic | 74.15% | 21.14% | |||
| Normalized Basic EPS | 74.92% | 21.14% | |||
| EPS Diluted | 74.15% | 21.14% | |||
| Normalized Diluted EPS | 74.92% | 21.14% | |||
| Average Basic Shares Outstanding | 0.50% | 0.67% | |||
| Average Diluted Shares Outstanding | 0.50% | 0.67% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
